Conditions: Atopic Dermatitis
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 109
Healthy volunteers: no

Brief summary:
The primary objective was to assess the clinical efficacy of repeated subcutaneous (SC) doses of Dupilumab in adult participants with moderate-to-severe atopic dermatitis (AD).

Detailed description:

Arms:
arm 1: Placebo (for Dupilumab) once weekly for 12 weeks by subcutaneous (SC) injection. arm 2: Dupilumab 300 mg once weekly for 12 weeks by SC injection.

Interventions: intervention 1: Placebo intervention 2: Dupilumab
Intervention descriptions: intervention 1: Subcutaneous injection altered between back of arms, abdomen and upper thighs. intervention 2: Subcutaneous injection altered between back of arms, abdomen and upper thighs.

Protocol document: